Provided by Tiger Trade Technology Pte. Ltd.

OS Therapies

1.68
+0.01500.90%
Volume:47.29K
Turnover:79.41K
Market Cap:77.26M
PE:-1.59
High:1.69
Open:1.68
Low:1.67
Close:1.66
52wk High:2.36
52wk Low:1.15
Shares:46.13M
Float Shares:33.71M
Volume Ratio:1.38
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0524
EPS(LYR):-0.9829
ROE:-914.04%
ROA:-232.65%
PB:-6.48
PE(LYR):-1.70

Loading ...

OS Therapies Management to Attend H.C. Wainwright Global Investment Conference

Reuters
·
2 hours ago

OS Therapies Launches $75 Million At-The-Market Offering

TIPRANKS
·
Aug 22

OS Therapies Launches USD 75 Million At-the-Market Equity Offering Via Jefferies

Reuters
·
Aug 22

Os Therapies - Enters Open Market Sale Agreement with Jefferies - SEC Filing

THOMSON REUTERS
·
Aug 22

Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Nicola Mining Inc. Unsponsored ADR (NICM)

TIPRANKS
·
Aug 18

OS Therapies Net Loss Widens to $19.03 Million in FY26 First Half; Revenue Remains no Revenue

Reuters
·
Aug 15

OS Therapies Wins FDA Type C Meeting to Review 2.5-Year Survival Data for OST-HER2 Phase 2b Osteosarcoma Trial

Reuters
·
Aug 13

OS Therapies Announces Convertible Note Financing and Warrants

TIPRANKS
·
Aug 13

Os Therapies - to Issue Senior Secured Convertible Notes up to $10 Mln in Private Placement - SEC Filing

THOMSON REUTERS
·
Aug 13

Os Therapies - Co & Its Wholly Owned Subsidiaries Entered Securities Purchase Agreement on August 10, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 13

OS Therapies Prices up to $10 Million Senior Secured Convertible Note Private Placement

Reuters
·
Aug 13

OS Therapies Agrees to Repay Leonite Debt in USD 1.9 Million Cash Settlement

Reuters
·
Aug 07

OS Therapies - Terminates at Market Issuance Sales Agreement on July 23, 2026 - SEC Filing

Reuters
·
Jul 30

OS Therapies Ends At-The-Market Equity Sales Program

TIPRANKS
·
Jul 30

Os Therapies - Termination of Sales Agreement Effective July 28, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 30

OS Therapies Announces Annual Shareholder Meeting

Reuters
·
Jul 25

OS Therapies Files Form 3 Showing Director Craig Eagle Holds no Securities

Reuters
·
Jul 24

OS Therapies Initiated at Buy by Roth Capital

Dow Jones
·
Jul 09

OS Therapies initiated with a Buy at Roth Capital

TIPRANKS
·
Jul 09

OS Therapies Accepts FDA CDER Meeting Request to Review Ost-her2 Biomarker Data

Reuters
·
Jul 08